GSK Grows Immuno-Oncology Credentials With New Dostarlimab Indication
Tumor-Agnostic Indication Approved In The US
GlaxoSmithKline’s checkpoint inhibitor Jemperli has gained a second indication in the US, for the treatment of mismatch repair-deficient solid tumors, affirming the company’s drive to develop a new portfolio of cancer therapies.
